Precigen INC Formerly Reported as Intrexon Corporation

Discovery and clinical stage biopharmaceutical company

Based in MD

Share:𝕏LinkedInFacebook
🤖

AI Overview

With $220K in lobbying spend across 11 quarterly filings, Precigen INC Formerly Reported as Intrexon Corporation is an active lobbying client. Their lobbying covers 3 issue areas. Active from 2018 to 2020.

$220K
Total Spend
3
Years Active
1
Firms Hired
1
Lobbyists Deployed
3
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2018$80K
2019$80K
2020$60K

Issues Lobbied

TradeAgricultureEnergy

Lobbying Firms

Bailey Strategic Advisors, LLC

Lobbyists

Roy Bailey

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Trade, Agriculture, Energy

  • •Import issues related to genetically modified food. No specific legislation.
  • •Issues relating to emerging energy technologies - no specific legislation.

Related Analysis

📈 Client Trajectories
See how this client compares to others over time
🎯 Market Concentration
How concentrated is the lobbying market?
🚀 Spending Momentum
Which issues are surging right now?

Related Investigations

The 2025 Tariff Panic
As tariffs return, lobbying on trade surges.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.

Similar Clients

Enviva INC. (FKA Enviva Holdings LP)
$2.3M total spend
Enviva LLC (Formerly Known as Enviva LP)
$1.7M total spend
Blue Diamond Growers
$1.3M total spend
Flexible Packaging Association
$700K total spend
Vestergaard Frandsen INC. Doing Business as Lifestraw
$580K total spend

Explore More

← All Clients⚖️ Compare Clients💵 ROI Calculator🔍 Investigations📖 How Lobbying Works🕸️ Network Analysis🏛️ Agency Pressure

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.